Peptide Research for High Cholesterol: Evidence-Based Guide 2026
This comprehensive, evidence-based guide examines the latest published research on peptides for high cholesterol, providing researchers with an in-depth analysis of molecular mechanisms, preclinical findings, clinical trial data, and practical implications for laboratory investigation. With the peptide research landscape evolving rapidly, staying current on peptides for high cholesterol has become essential for investigators designing rigorous experimental protocols.
Over the past decade, research into peptides for high cholesterol has produced a substantial body of peer-reviewed evidence, spanning hundreds of published studies across leading scientific journals. This guide synthesizes the most impactful findings, highlights critical knowledge gaps, and identifies emerging research directions that are reshaping the field.
Whether you are an experienced peptide researcher or exploring this domain for the first time, this guide provides the scientific context needed to evaluate published evidence and design informed experiments. For high-purity research compounds, explore our complete selection of research peptides with third-party testing and Certificates of Analysis.
Table of Contents
- Structure-Activity Relationships
- Biomarker Analysis and Outcome Measures
- Genomic and Transcriptomic Evidence
- Dose-Response Data and Optimal Concentrations
- Receptor Pharmacology and Binding Data
- Comparative Analysis with Alternatives
- In Vitro Research Findings
- Emerging Applications and Future Directions
- Research Protocol Recommendations
- Combination Research and Synergistic Effects
- Pharmacokinetic Profile and Bioavailability
- FAQ
- Shop Peptides
Structure-Activity Relationships
Understanding structure-activity relationships is fundamental to comprehensive peptides for high cholesterol investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Longitudinal research tracking peptides for high cholesterol effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
For laboratory work, Semaglutide and MOTS-C are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The cumulative evidence provides a solid foundation for continued peptides for high cholesterol investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Zhang et al., 2020, establishing critical parameters for understanding these mechanisms.
Biomarker Analysis and Outcome Measures
The scientific literature on biomarker analysis and outcome measures provides critical insights into peptides for high cholesterol research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Studies examining peptides for high cholesterol have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
Related research compounds include AOD 9604 and Tirzepatide, available with purity documentation from Proxiva Labs.
The cumulative evidence provides a solid foundation for continued peptides for high cholesterol investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Dorling et al., 2019, establishing critical parameters for understanding these mechanisms.
Genomic and Transcriptomic Evidence
The scientific literature on genomic and transcriptomic evidence provides critical insights into peptides for high cholesterol research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Quantitative analysis of peptides for high cholesterol in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
These findings demonstrate the multifaceted nature of peptides for high cholesterol research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Gomes et al., 2013, establishing critical parameters for understanding these mechanisms.
Dose-Response Data and Optimal Concentrations
Investigation of dose-response data and optimal concentrations represents an active frontier in peptides for high cholesterol research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Quantitative analysis of peptides for high cholesterol in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
Researchers investigating these mechanisms can access high-purity compounds including Semaglutide and MOTS-C from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
These findings demonstrate the multifaceted nature of peptides for high cholesterol research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Munoz-Espin et al., 2014, establishing critical parameters for understanding these mechanisms.
Receptor Pharmacology and Binding Data
Research into receptor pharmacology and binding data has generated substantial evidence illuminating how peptides for high cholesterol interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Longitudinal research tracking peptides for high cholesterol effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
Researchers investigating these mechanisms can access high-purity compounds including Semaglutide and MOTS-C from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The cumulative evidence provides a solid foundation for continued peptides for high cholesterol investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Deacon et al., 2020, establishing critical parameters for understanding these mechanisms.
Comparative Analysis with Alternatives
Research into comparative analysis with alternatives has generated substantial evidence illuminating how peptides for high cholesterol interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Quantitative analysis of peptides for high cholesterol in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
Published studies frequently employ high-purity research compounds. Semaglutide and MOTS-C from Proxiva Labs meet stringent purity requirements, verified by independent testing.
These findings demonstrate the multifaceted nature of peptides for high cholesterol research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Baker et al., 2016, establishing critical parameters for understanding these mechanisms.
In Vitro Research Findings
Research into in vitro research findings has generated substantial evidence illuminating how peptides for high cholesterol interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Quantitative analysis of peptides for high cholesterol in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
The cumulative evidence provides a solid foundation for continued peptides for high cholesterol investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Galluzzi et al., 2017, establishing critical parameters for understanding these mechanisms.
Emerging Applications and Future Directions
The scientific literature on emerging applications and future directions provides critical insights into peptides for high cholesterol research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to peptides for high cholesterol. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
Related research compounds include Retatrutide and BPC-157 Oral Tablets, available with purity documentation from Proxiva Labs.
The cumulative evidence provides a solid foundation for continued peptides for high cholesterol investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Levine & Kroemer, 2019, establishing critical parameters for understanding these mechanisms.
Research Protocol Recommendations
Research into research protocol recommendations has generated substantial evidence illuminating how peptides for high cholesterol interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to peptides for high cholesterol. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
Published studies frequently employ high-purity research compounds. Semaglutide and MOTS-C from Proxiva Labs meet stringent purity requirements, verified by independent testing.
The cumulative evidence provides a solid foundation for continued peptides for high cholesterol investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Rajman et al., 2018, establishing critical parameters for understanding these mechanisms.
Combination Research and Synergistic Effects
Research into combination research and synergistic effects has generated substantial evidence illuminating how peptides for high cholesterol interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to peptides for high cholesterol. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
For laboratory work, Semaglutide and MOTS-C are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The cumulative evidence provides a solid foundation for continued peptides for high cholesterol investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Xu et al., 2018, establishing critical parameters for understanding these mechanisms.
Pharmacokinetic Profile and Bioavailability
Understanding pharmacokinetic profile and bioavailability is fundamental to comprehensive peptides for high cholesterol investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Longitudinal research tracking peptides for high cholesterol effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
For laboratory work, Semaglutide and MOTS-C are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
These findings demonstrate the multifaceted nature of peptides for high cholesterol research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Mottis et al., 2019, establishing critical parameters for understanding these mechanisms.
Additional Research Perspectives
The scientific literature on additional research perspectives provides critical insights into peptides for high cholesterol research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Quantitative analysis of peptides for high cholesterol in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
Related research compounds include Tirzepatide and TB-500 (Thymosin Beta-4), available with purity documentation from Proxiva Labs.
The cumulative evidence provides a solid foundation for continued peptides for high cholesterol investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Jeong et al., 2019, establishing critical parameters for understanding these mechanisms.
Frequently Asked Questions
How should researchers study peptides for high cholesterol?
Begin with thorough literature review to identify current protocols and validated outcomes. Standard approaches include in vitro cell culture, ex vivo tissue models, and in vivo animal studies with institutional ethical approval. Proper controls, randomization, and blinding are essential.
Where can I find high-quality research peptides?
Proxiva Labs offers research-grade peptides with ?98% HPLC purity and Certificates of Analysis. Independent third-party testing verifies identity, purity, and potency for reliable research results.
What equipment is needed?
Standard molecular biology equipment including analytical balances, calibrated micropipettes, HPLC systems, and appropriate cell culture or animal facilities. Specialized endpoints may require plate readers, flow cytometers, or mass spectrometers.
How long until results are visible?
Timelines vary by model and endpoint. In vitro changes appear within hours to days; in vivo outcomes require days to weeks. Chronic studies may extend months. Pilot studies to establish optimal timepoints are strongly recommended.
What does the research say about peptides for high cholesterol?
Peer-reviewed literature on peptides for high cholesterol spans multiple journals, providing growing evidence supporting continued investigation. Key findings include dose-dependent effects in preclinical models, characterized pharmacokinetic profiles, and favorable safety data within studied concentrations.
What is peptides for high cholesterol?
Peptides for high cholesterol encompasses a specific area of peptide science attracting significant research interest due to potential applications in biological research. Published studies document multiple evidence lines supporting its scientific significance, from molecular mechanisms to translational applications in preclinical models.
What mistakes should researchers avoid?
Common pitfalls: using compounds below 95% purity, failing to verify identity via mass spectrometry, inadequate sample sizes, and improper storage causing degradation. Always source from suppliers with verified purity documentation.
Is this research clinically relevant?
While most peptides for high cholesterol research is preclinical, translational potential is considerable. Related compounds have progressed through clinical trials. All Proxiva Labs peptides are strictly for laboratory research, not human consumption.
Related Research Resources
Explore more from Proxiva Labs:
- Tirzepatide — a dual GIP/GLP-1 receptor agonist with emerging metabolic research applications
- TB-500 (Thymosin Beta-4) — a 43-amino acid peptide studied for tissue regeneration and anti-inflammatory effects
- Semax — a synthetic ACTH analog studied for neuroprotective and cognitive effects
- BPC-157 — a gastric pentadecapeptide studied for tissue repair and wound healing
- Klow — a proprietary peptide blend studied for recovery and anti-inflammatory support
- Browse All Research Guides
- Shop All Peptides
- Third-Party Test Results
Shop Research Peptides at Proxiva Labs
USA-Made • ?98% HPLC Purity • Third-Party Tested • Free Shipping $150+ • COA Included
a GLP-1 receptor agonist studied for metabolic and weight management research
a mitochondrial-derived peptide studied for metabolic regulation and exercise mi
an amino acid derivative studied for fatty acid transport and energy metabolism
a copper-binding tripeptide studied for skin remodeling and gene expression modu
a proprietary peptide blend studied for recovery and anti-inflammatory support
a modified GH fragment studied for lipolytic activity and fat metabolism
a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors
an alpha-MSH fragment studied for anti-inflammatory and antimicrobial effects